Figure 1

Activation of MEK1/2, ERK1/2 or MNK1/2 in RVLM sustained central cardiovascular regulation associated with experimental brain stem death. Temporal changes in mean systemic arterial pressure (MSAP), hear rate (HR) or power density of low-frequency (LF) component of SAP signals in rats that received pretreatment by microinjection bilaterally into RVLM of vehicle (Veh; aCSF or 0.2% DMSO), ERK activation inhibitor peptide II (Peptide II; ERK2 inhibitor), U0126 (MEK1/2 inhibitor) or CGP57380 (MNK1/2 inhibitor), 30 min before local application (at arrow) of aCSF or Mev (10 nmol) to the bilateral RVLM. Values are mean ± SEM, n = 5-7 animals per experimental group. *P < 0.05 versus Veh+aCSF group, and ⁺P < 0.05 versus Veh+Mev group at corresponding time-points in the Scheffé multiple-range test.